Collierville, TN, United States of America

Devesh Srivastava



Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Devesh Srivastava: Innovator in Nuclear Receptor Binding Agents

Introduction

Devesh Srivastava is a notable inventor based in Collierville, TN (US). He has made significant contributions to the field of medical science through his innovative work on nuclear receptor binding agents. His research focuses on developing solutions for various diseases and conditions.

Latest Patents

Devesh holds a patent for nuclear receptor binding agents, which are applicable in the prevention and treatment of a variety of diseases. These include cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, and oxidative stress-related disorders like Parkinson's and stroke. His invention also addresses neurological disorders, ophthalmic disorders, cardiovascular disease, and obesity. This patent highlights his commitment to advancing medical treatments and improving patient outcomes. He has 1 patent to his name.

Career Highlights

Devesh is currently associated with Gtx Corporation, where he continues to innovate and contribute to the field of medical research. His work is characterized by a strong focus on developing effective therapeutic agents that can significantly impact healthcare.

Collaborations

Some of his notable coworkers include James T Dalton and Duane Douglas Miller. Their collaboration enhances the research environment and fosters innovation within the company.

Conclusion

Devesh Srivastava is a dedicated inventor whose work on nuclear receptor binding agents has the potential to transform the treatment landscape for various diseases. His contributions reflect a deep commitment to improving health outcomes through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…